Immix Biopharma, Inc. Annual Net Income (Loss) Attributable to Parent in USD from 2020 to 2023

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Immix Biopharma, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2020 to 2023.
  • Immix Biopharma, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$7.15M, a 67% decline year-over-year.
  • Immix Biopharma, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$21.9M, a 54.9% decline year-over-year.
  • Immix Biopharma, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$15.4M, a 87.4% decline from 2022.
  • Immix Biopharma, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$8.23M, a 66.2% increase from 2021.
  • Immix Biopharma, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$24.4M, a 2024% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$15.4M -$7.2M -87.4% Jan 1, 2023 Dec 31, 2023 10-K 2024-03-29
2022 -$8.23M +$16.2M +66.2% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-29
2021 -$24.4M -$23.2M -2024% Jan 1, 2021 Dec 31, 2021 10-K 2022-03-28
2020 -$1.15M Jan 1, 2020 Dec 31, 2020 10-K 2022-03-28
* An asterisk sign (*) next to the value indicates that the value is likely invalid.